Block 7 commercial production in Q2 FY27
Block 7 expansion is on track and expected to commence commercial production in Q2 of FY27, supporting niche molecules including graphene.
SHREEGANESHREMEDIES / guidance tracker
Keep management guidance in view.
Shree Ganesh Remedies · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
expansion
Graphene projects to commercial trials in FY27
Pilot trials for graphene projects completed; commercial trials expected to start in FY27, with commercial production later in the year subject to approvals.
Long-term EBITDA margin guidance 26-28%
Management reiterated sustainable EBITDA margin range of 26-28% over the long term, though initial product approvals may yield higher margins.
Block 8 to reach full utilization by end of FY27
Block 8 capacity utilization is expected to reach its peak by the end of FY27.